CPBIO Holding Company Limited
Research CPBIO Holding Company Limited (3839.HK) on Bullrun: market cap HKD 1.90B, P/E 10.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3839.HK
- ExchangeHK
- CountryHong Kong
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 1.90B
- P/E10.5
- Financial periodFY2025
- RevenueUSD 535.91M
- Revenue growth74.1%
- Net incomeUSD 32.06M
- Free cash flowUSD 28.04M
- Gross margin14.4%
Valuation Snapshot
latest market cap is HKD 1.90B; P/E is 10.5.
Peer valuation comparison
Latest P/E is 10.53x versus a Healthcare sector median of 21.69x (51.4% below).
Latest P/E is 10.53x versus a Hong Kong median of 10.3x (2.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 535.91M | USD 32.06M | USD 28.04M | 14.4% | 0.13 | USD 39.83M | USD 47.87M | USD 277.15M |
| FY2024 | USD 307.75M | USD 11.17M | -USD 2.56M | 15.9% | 0.04 | USD 32.38M | USD 69.17M | USD 234.77M |
| FY2023 | USD 173.98M | USD 2.55M | -USD 27.17M | 17.3% | 0.01 | USD 37.61M | USD 78.17M | USD 228.43M |
| FY2022 | USD 159.24M | -USD 6.68M | -USD 10.38M | 24.6% | -0.03 | USD 30.86M | USD 49.10M | USD 230.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.90B | 10.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About CPBIO Holding Company Limited
CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CPBIO Holding Company Limited's market cap?
CPBIO Holding Company Limited's market capitalization is HKD 1.90B.
What is CPBIO Holding Company Limited's P/E ratio?
CPBIO Holding Company Limited's price-to-earnings (P/E) ratio is 10.5.
What does CPBIO Holding Company Limited do?
CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names.